［1］Siegel RL，Miller KD，Jemal A.Cancer statistics，2016［J］.CA Cancer J Clin，2016，66(1)：7-30.
［2］Besse B，Adjei A，Baas P，et al.2nd ESMO consensus conference on lung cancer：Non-small cell lung cancer first-line/second and further lines of treatment in advanced disease［J］.Ann Oncol，2014，25(8)：1475-1484.
［3］Reck M，Popat S，Reinmuth N，et al.Metastatic non-small cell lung cancer(NSCLC)：ESMO Clinical practice guidelines for diagnosis，treatment and follow-up［J］.Ann Oncol，2014，25(Suppl 3)：27-39.
［4］Alevizakos M，Kaltsas S，Syrigos KN.The VEGF pathway in lung cancer［J］.Cancer Chemother Pharmacol，2013，72(6)：1169-1181.
［5］Johnson DH，Fehrenbacher L，Novotny WF，et al.Randomized phase Ⅱ trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancer［J］.J Clin Oncol，2004，22(11)：2184-2191.
［6］Crino L，Dansin E，Garrido P，et al.Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small cell lung cancer(SAiL，MO19390)：A phase 4 study［J］.Lancet Oncol，2010，11(8)：733-740.
［7］Reck M，Barlesi F，Crino L，et al.Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab：A consensus report from a panel of experts［J］.Ann Oncol，2012，23(5)：1111-1120.
［8］Sandler A，Gray R，Perry MC，et al.Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer［J］.N Engl J Med，2006，355(24)：2542-2550.
［9］Reck M，Von Pawel J，Zatloukal P，et al.Phase Ⅲ trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small cell lung cancer：AVAil［J］.J Clin Oncol，2009，27(8)：1227-1234.
［10］Zhou C，Wu YL，Chen G，et al.BEYOND：A randomized，double-blind，placebo-controlled，multicenter，phase Ⅲ study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in chinese patients with advanced or recurrent nonsquamous non-small cell lung cancer［J］.J Clin Oncol，2015，33(19)：2197-2204.
［11］Soria JC，Mauguen A，Reck M，et al.Systematic review and Meta-analysis of randomised，phase Ⅱ/Ⅲ trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small cell lung cancer［J］.Ann Oncol，2013，24(1)：20-30.
［12］Behera M，Pillai RN，Owonikoko TK，et al.Bevacizumab in combination with taxane versus non-taxane containing regimens for advanced/metastatic nonsquamous non-small cell lung cancer：A systematic review［J］.J Thorac Oncol，2015，10(8)：1142-1147.
［13］Lynch TJ，Spigel DR，Brahmer J，et al.Safety and effectiveness of bevacizumab-containing treatment for non-small cell lung cancer：Final results of the ARIES observational cohort study［J］.J Thorac Oncol，2014，9(9)：1332-1339.
［14］Lopez-Chavez A，Young T，Fages S，et al.Bevacizumab maintenance in patients with advanced non-small cell lung cancer，clinical patterns，and outcomes in the Eastern Cooperative Oncology Group 4599 Study：Results of an exploratory analysis［J］.J Thorac Oncol，2012，7(11)：1707-1712.
［15］Barlesi F，Scherpereel A，Rittmeyer A，et al.Randomized phase Ⅲ trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab，cisplatin，and pemetrexed in advanced nonsquamous non-small cell lung cancer：AVAPERL(MO22089)［J］.J Clin Oncol，2013，31(24)：3004-3011.
［16］Patel JD，Socinski MA，Garon EB，et al.Pointbreak：A randomized phase Ⅲ study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage Ⅲb or Ⅳ nonsquamous non-small cell lung cancer［J］.J Clin Oncol，2013，31(34)：4349-4357.
［17］Zinner RG，Obasaju CK，Spigel DR，et al.PRONOUNCE：Randomized，open-label，phase Ⅲ study of first-line pemetrexed+carboplatin followed by maintenance pemetrexed versus paclitaxel+carboplatin+bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small cell lung cancer［J］.J Thorac Oncol，2015，10(1)：134-142.
［18］Gridelli C，Rossi A，Ciardiello F，et al.BEVERLY：Rationale and design of a randomized open-label phase Ⅲ trial comparing bevacizumab plus erlotinib versus erlotinib alone as first-line treatment of patients with EGFR-mutated advanced nonsquamous non-small cell lung cancer［J］.Clin Lung Cancer，2016，17(5)：461-465.
［19］Herbst RS，Ansari R，Bustin F，et al.Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small cell lung cancer after failure of standard first-line chemotherapy(BeTa)：A double-blind，placebo-controlled，phase 3 trial［J］.Lancet，2011，377(9780)：1846-1854.
［20］Seto T，Kato T，Nishio M，et al.Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small cell lung cancer harbouring EGFR mutations (JO25567)：An open-label，randomised，multicentre，phase 2 study［J］.Lancet Oncol，2014，15(11)：1236-1244.
［21］Rosell R，Dafni U，Felip E，et al.Erlotinib and bevacizumab in patients with advanced non-small cell lung cancer and activating EGFR mutations(BELIEF)：An international，multicentre，single-arm，phase 2 trial［J］.Lancet Respir Med，2017，5(5)：435-444.
［22］Lanitis E，Irving M，Coukos G.Targeting the tumor vasculature to enhance T cell activity［J］.Curr Opin Immunol，2015，33：55-63.
［23］Kwilas AR，Donahue RN，Tsang KY，et al.Immune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy［J］.Cancer Cell Microenviron，2015，2(1)：e677.
［24］Rizvi NA，Antonia SJ，Shepherd FA，et al.Nivolumab(anti-PD-1；BMS-936558，ONO-4538) maintenance as monotherapy or in combination with bevacizumab(bev) for non-small cell lung cancer(NSCLC) previously treated with chemotherapy［J］.International Journal of Radiation Oncology Biology Physics，2014，90(5)：S32.
［25］Cooper MR，Binkowski C，Hartung J，et al.Profile of ramucirumab in the treatment of metastatic non-small cell lung cancer［J］.Onco Targets Ther，2016，4(9)：1953-1960.
［26］Camidge DR，Berge EM，Doebele RC，et al.A phase Ⅱ，open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage Ⅲb/Ⅳ non-small cell lung cancer［J］.J Thorac Oncol，2014，9(10)：1532-1539.
［27］Doebele RC，Spigel D，Tehfe M，et al.Phase 2，randomized，open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous，advanced/metastatic non-small cell lung cancer［J］.Cancer，2015，121(6)：883-892.
［28］Garon EB，Ciuleanu TE，Arrieta，et al.Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage Ⅳ non-small cell lung cancer after disease progression on platinum-based therapy(REVEL)：A multicentre，double-blind，randomised phase 3 trial［J］.Lancet，2014，384(9944)：665-673.
［29］Garon EB，Reck M，Paz-Ares L，et al.Treatment rationale and study design for the RELAY Study：A multicenter，randomized，double-blind study of erlotinib with ramucirumab or placebo in patients with epidermal growth factor receptor mutation-positive metastatic non-small cell lung cancer［J］.Clin Lung Cancer，2017，18(1)：96-99.
［30］Herbst RS，Bendell JC，Isambert N，et al.A phase 1 study of ramucirumab(R) plus pembrolizumab(P) in patients(pts) with advanced gastric or gastroesophageal junction(G/GEJ) adenocarcinoma，non-small cell lung cancer(NSCLC)，or urothelial carcinoma (UC)：Phase 1a Results［J］.J Clin Oncol，2016，34(Suppl)：abstr 3056.
［31］Mcdougall SR，Anderson AR，Chaplain MA.Mathematical modelling of dynamic adaptive tumour-induced angiogenesis：Clinical implications and therapeutic targeting strategies［J］.J Theor Biol，2006，241(3)：564-589.
［32］Skouras VS，Maragkos C，Grapsa D，et al.Targeting neovasculature with multitargeted antiangiogenesis tyrosine kinase inhibitors in non-small cell lung cancer［J］.Bio Drugs，2016，30(5)：421-439.
［33］Rolfo C，Raez LE，Bronte G，et al.BIBF 1120/nintedanib：A new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer［J］.Expert Opin Investig Drugs，2013，22(8)：1081-1088.
［34］Reck M，Kaiser R，Eschbach C，et al.A phase Ⅱ double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small cell lung cancer［J］.Ann Oncol，2011，22(6)：1374-1381.
［35］Reck M，Kaiser R，Mellemgaard A，et al.Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small cell lung cancer(LUME-Lung 1)：A phase 3，double-blind，randomised controlled trial［J］.Lancet Oncol，2014，15(2)：143-155.
［36］Popat S，Mellemgaard A，Fahrbach K，et al.Nintedanib plus docetaxel as second-line therapy in patients with non-small cell lung cancer：A network meta-analysis［J］.Future Oncol，2015，11(3)：409-420.
［37］Hanna NH，Kaiser R，Sullivan RN，et al.Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory，advanced non-small cell lung cancer(LUME-Lung 2)：A randomized，double-blind，phase Ⅲ trial［J］.Lung Cancer，2016，102：65-73.
［38］Sun Y，Niu W，Du F，et al.Safety，pharmacokinetics，and antitumor properties of anlotinib，an oral multi-target tyrosine kinase inhibitor，in patients with advanced refractory solid tumors［J］.J Hematol Oncol，2016，9(1)：105.
［39］Han B，Li K，Zhao Y，et al.113 panlotinib as third-line treatment in patients with refractory advanced non-small cell lung cancer：A multicentre，randomized，double-blind，placebo-controlled，phase Ⅱ trial (NCT01924195)［J］.Annals of Oncology，2015，26(suppl 1)：i36-i36.
［40］Han B，Li K，Wang Q，et al.Efficacy and safety of third-line treatment with anlotinib in patients with refractory advanced non-small cell lung cancer(ALTER-0303)：A randomised，double-blind，placebo-controlled phase 3 study［J］.Lancet Oncology，2017，18(1)：S3.
［41］Wang J，Sun Y，Liu Y，et al.Results of randomized，multicenter，double-blind phase Ⅲ trial of rh-endostatin(YH-16) in treatment of advanced non-small cell lung cancer patients［J］.Chin J Oncol，2005，8(4)：283-290.
［42］Sun Y，Wang JW，Liu YY，et al.Long-term results of a randomized，double-blind，and placebo-controlled phase Ⅲ trial：Endostar(rh-endostatin) versus placebo in combination with vinorelbine and cisplatin in advanced non-small cell lung cancer［J］.Thoracic Cancer，2013，4(4)：440-448.
［43］Han BH，Xiu QY，Wang HM，et al.A multicenter，randomized，double-blind，placebo-controlled safety study to evaluate the clinical effects and quality of life of paclitaxel-carboplati(PC) alone or combined with endostar for advanced non-small cell lung cancer(NSCLC)［J］.Chin J Oncol，2011，33(11)：854-859.
［44］Zhao X，Mei K，Cai X，et al.A randomized phase Ⅱ study of recombinant human endostatin plus gemcitabine/cisplatin compared with gemcitabine/cisplatin alone as first-line therapy in advanced non-small cell lung cancer［J］.Invest New Drugs，2012，30(3)：1144-1149.
［45］Hu W，Fang J，Nie J，et al.Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced nonsmall cell lung cancer［J］.Medicine，2016，95(28)：e4183.
［46］Zhao Q，Peng L，Chen F，et al.Icotinib and rh-endostatin as first line therapy in advanced non small cell line cancer patients harboring activating epidermal growth factor receptor mutations［J］.J Clin Oncol，2016，34(15)：e20074.